v3.26.1
Related Party Transactions
12 Months Ended
Dec. 31, 2025
Related Party Transactions [Abstract]  
Related Party Transactions

15. Related Party Transactions

In May 2025, the Company made a final payment of $6.3 million to Amgen under the Amgen Collaboration Agreement for research and development activities. The parties agreed that this is the final amount due under the agreement. Research and development expenses related to the Amgen Collaboration Agreement were $6.3 million and $12.5 million for the years ended December 31, 2025 and 2024, respectively.